Scientific Online Resource System

Scripta Scientifica Medica

2-year single center clinical experience in patients with colon cancer stage II and III receiving adjuvant chemotherapy

Nikolay Vladimirov Conev, Ivan Shterev Donev, Eleonora Dimitrova, Miglena Kozhuharova, Margarita Georgieva, Assia Konsoulova-Kirova, Dimitar Kalev

Abstract

Introduction: Colorectal cancer is the most commonly diagnosed gastrointestinal cancer worldwide. For patients without metastatic disease, surgery is the first option used with curative intention, for stage I disease the adequate treatment consists only of surgical excision. In stage III additional adjuvant chemotherapy post-surgery is recommended. In stage II colon cancer, adjuvant treatment remains controversial.

We aim to stratify patients according to different criteria, identify those with recurrence within the first year post last cycle of adjuvant chemotherapy and discuss those primary results.

Materials and methods: a total of 52 patients who were subject to curative resection of stage II and III colon adenocarcinoma and who were administrated 5 FU based adjuvant chemotherapy were included and were followed for a period of two years. Data analysis was performed.

Result: After a mean of 2 years of follow-up, recurrence was identified in 16 patients. None of stage II patients (n=6) and 3 patients in stage III (n=6) experienced recurrence. Patients with Nx cancer (n=30) were detached in separate group. Thirteen of them experienced recurrence (9 patients had relapse within 6 months after surgery - defined as synchronous metastatic disease).

Conclusion: Surgery remains the cornerstone of treatment for the majority of colon patients. The selection of optimal chemotherapy for each patient is a complex process and there is a practice evidence gap which remains a significant problem. Our results for relapse are comparable with the reported ones worldwide. The reports suggest that there is still lack of evidence in the adjuvant colon cancer chemotherapy worldwide.


Keywords

colon cancer; adjuvant chemotherapy; recurrence; early stages colon cancer; follow-up

Full Text


References

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4):212-236.

National Statistical Institute Bulgaria "Health care 2013" http://www.nsi.bg/bg/content/12020/%D0%BF%D1%83%D0%B1%D0%BB%D0%B8%D0%BA%D0%B0%D1%86%D0%B8%D1%8F/%D0%B7%D0%B4%D1%80%D0%B0%D0%B2%D0%B5%D0%BE%D0%BF%D0%B0%D0%B7%D0%B2%D0%B0%D0%BD%D0%B5-2013. Bulgarian,

http://www.cancer.gov/cancertopics/diagnosis-staging/staging/staging-fact-sheet CsNCIRJ: 2013.

Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009. 27(19):3109-3116.

Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 2011. 47(7):990-996.

Chau I, Cunningham D. Adjuvant therapy in colon cancer--what, when and how? Ann Oncol. 2006;17(9):1347-1359.

Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020-2029.

Harrell FE, Jr., Lee KL, Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15(4):361-387.

Nordlinger B, Benoist S. Liver metastases from colorectal cancer: a multidisciplinary approach is necessary. Bull Acad Natl Med 2008;192(1):33-43;discussion 44.

Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010, 17(6):1471-1474.

Harris GJ, Church JM, Senagore AJ, Lavery IC, Hull TL, Strong SA, Fazio VW. Factors affecting local recurrence of colonic adenocarcinoma. Dis Colon Rectum. 2002, 45(8):1029-1034.

Cunliffe WJ, Hasleton PS, Tweedle DE, Schofield PF. Incidence of synchronous and metachronous colorectal carcinoma. Br J Surg. 1984, 71(12):941-943.

Ivanov K, Kolev N, Shterev I, Tonev A, Ignatov V, Bojkov V, Kirilova T. Adjuvant Treatment in Colorectal Cancer. Therapy. 2014;4:5.

Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003; 21(15):2912-2919.

Ratto C, Sofo L, Ippoliti M, Merico M, Bossola M, Vecchio FM, Doglietto GB, Crucitti F. Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis Colon Rectum. 1999;42(2):143-154; discussion 154-148.

Tsikitis VL, Larson DW, Huebner M, Lohse CM, Thompson PA. Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer. 2014;14:336.




DOI: http://dx.doi.org/10.14748/ssm.v47i2.1223

Refbacks

About The Authors

Nikolay Vladimirov Conev
Medical university of Varna
Bulgaria

Medical oncology clinic

Ivan Shterev Donev
Medical university of Varna
Bulgaria

Medical oncology clinic

Eleonora Dimitrova
Medical university of Varna
Bulgaria

Medical oncology clinic

Miglena Kozhuharova
Medical university of Varna
Bulgaria

Medical oncology clinic

Margarita Georgieva
Medical university of Varna
Bulgaria

Medical oncology clinic

Assia Konsoulova-Kirova
Medical university of Varna
Bulgaria

Medical oncology clinic

Dimitar Kalev
Medical university of Varna
Bulgaria

Medical oncology clinic

Font Size


|